IP Library Granted Patent US 9,364,479
Granted Patent B2
US 9,364,479 · App. 13/818,844 · Granted Jun 14, 2016

Use of a receptor-type kinase modulator for treating polycystic kidney disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,364,479
App. No.
13/818,844
Granted
Jun 14, 2016
Kind
B2
Abstract

The invention comprises use of a therapeutically effective amount of the compound of the formula below for preparation of a medicament for treating polycystic kidney diseases (PKD) in a mammal, such as human or feline (e.g., Persian cat). Formula (I). Also provided are the above compound and compositions comprising it for treating PKD.

Claims (9)

1. A method of treating polycystic kidney disease (PKD) in a mammal, the method comprising administering a therapeutically effective amount of a compound of formula

or a pharmaceutically acceptable salt thereof, to a mammal having PKD.

2. The method of claim 1 wherein the mammal is a human.

3. The method of claim 1 wherein the mammal is a feline.

4. The method of claim 3 wherein the feline is a Persian cat.

5. The method of claim 1 where the compound is delivered in the form of a pharmaceutical composition comprising the compound or a salt thereof and a pharmaceutically acceptable carrier, excipient, and/or diluent.

6. The method of claim 2 where the compound is delivered in the form of a pharmaceutical composition comprising the compound or a salt thereof and a pharmaceutically acceptable carrier, excipient, and/or diluent.

7. The method of claim 3 where the compound is delivered in the form of a pharmaceutical composition comprising the compound or a salt thereof and a pharmaceutically acceptable carrier, excipient, and/or diluent.

8. The method of claim 4 where the compound is delivered in the form of a pharmaceutical composition comprising the compound or a salt thereof and a pharmaceutically acceptable carrier, excipient, and/or diluent.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Oct 29, 2021
From: MACQUARIE US TRADING LLC
To: KADMON CORPORATION, LLC
Reel/Frame 057973/0751 →
TERMINATION OF PATENT AND TRADEMARK SECURITY AGREEMENT Recorded Nov 25, 2019
From: PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP
To: KADMON CORPORATION, LLC
Reel/Frame 051106/0677 →
SECURITY INTEREST Recorded Sep 8, 2015
From: KADMON CORPORATION, LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 036573/0001 →
SECURITY INTEREST Recorded Aug 31, 2015
From: KADMON CORPORATION, LLC
To: PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP
Reel/Frame 036515/0084 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2013
From: FROST, PHILIP; LIAO, WILLIAM W.N.; ROWINSKY, ERIC K.
To: PRIMROSE THERAPEUTICS, INC.
Reel/Frame 030508/0076 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2013
From: PRIMROSE THERAPEUTICS, INC.
To: SYMPHONY EVOLUTION, INC.
Reel/Frame 030508/0082 →